Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086256 | 1.00 | PDE4B (0.44) | PDE4BMAPTGPR119PAK1HDAC1 | |
| SCHEMBL3082480 | 1.00 | PDE4B (0.44) | PDE4BMAPTGPR119PAK1HDAC1 | |
| SCHEMBL15321868 | 0.88 | NR1H2 (0.44) | PDE4BMAPTGPR119HDAC1HDAC2 | |
| SCHEMBL16286806 | 0.85 | PIN1 (0.43) | PDE4BGPR119PAK1HDAC1HDAC2 | |
| SCHEMBL16286536 | 0.85 | PIN1 (0.43) | PDE4BGPR119PAK1HDAC1HDAC2 | |
| SCHEMBL16297211 | 0.85 | PIN1 (0.43) | PDE4BGPR119PAK1HDAC1HDAC2 | |
| SCHEMBL16297213 | 0.85 | PIN1 (0.43) | PDE4BGPR119PAK1HDAC1HDAC2 | |
| SCHEMBL16286472 | 0.85 | PIN1 (0.43) | PDE4BGPR119PAK1HDAC1HDAC2 | |
| SCHEMBL27900160 | 0.85 | MGLL (0.40) | — | |
| SCHEMBL16286484 | 0.84 | SMN1; SMN2 (0.48) | PDE4BGPR119PAK1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2079693-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052899-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | PDE4B 2155/4885MAPT 36/4885GPR119 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.